CAC 40
7 690,66 +62,09 (+0,81 %) Euro Stoxx 50
4 943,15 +35,85 (+0,73 %) Dow Jones
39 150,33 +15,53 (+0,04 %) EUR/USD
1,0739 +0,0041 (+0,39 %) Gold future
2 340,00 +8,80 (+0,38 %) Bitcoin EUR
56 868,72 -2 982,92 (-4,98 %)
Aurobindo Pharma Limited (AUROPHARMA.BO)
Aurobindo Pharma Limited
Galaxy, Plot No. 1
22nd-24th Floor Plot No.1, Survey No.83/1 Hyderabad Knowledge City,Raidurg Panmakt
Hyderabad 500032
India
91 40 6672 5000
https://www.aurobindo.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein:
Description
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Aurobindo Pharma Limited en date du 1 juin 2024 est 1. Les scores principaux sont Audit : 6; Société : 2; Droits des actionnaires : 1; Compensation : 1.
